PTK2 and neoplasm: After completion of the treatment period, Western blot analysis of tumor samples harvested from NUGC-4 CDX model mice showed that p-FAK was upregulated to significantly higher levels in the crizotinib monotherapy group compared with that in the combination treatment group (Figure 3 E), suggesting that FAK inhibition by IN10018 administration could suppress the activation of FAK signaling associated with crizotinib.